


The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase



Supplementary Figure 1: MCF7 cells that stably express aromatase produce estrogen in response to androstenedione and become sensitive to inhibitors of the estrogen signaling pathway. (A) Estrogen production as measured by ELISA from MCF7 parental controls and MCF7-ARO cells. (B) Cell potency of taselisib, letrozole, and tamoxifen was determined in a 96-hour viability assay. Error bars indicate standard deviation around the mean.



Supplementary Figure 2: MCF7-ARO Resistant pools are significantly more resistant estrogen therapies, compared to the parental MCF7-ARO line. Cell potency of tamoxifen and exemestane was determined in a 96-hour viability assay. Error bars indicate standard deviation around the mean.




Supplementary Figure 3: Increased p110 α protein expression is not due to increased gene expression.

PIK3CA expression (normalized to housekeeping genes) was determined in parental and letrozole resistant MCF7-ARO clones.



B.



Supplementary Figure 4: Commonly described mechanisms of endocrine therapy resistance do suggest mechanisms of resistance in the MCF7-ARO line. (A) Increasses in MET, RET, FOSL1, and BCL2 are detected in letrozole resistant MCF7-ARO cells. Protein changes with letrozole and taselisib treatments are shown by immunoblot. Treatments are for 24 hrs with 0.1 μM taselisib and/or 0.1μM letrozole. (B) siRNA Knockdown of FOSL1 does not sensitize. Immunoblots for FOSL1 are from the 48 hr timepoint. Cell potency of letrozole in the MCF7-ARO letrozole resistant cell line was determined in a 96-hour viability assay. (C) Sensitivity of XL184, PF-02341066, and GDC-0199 in the letrozole resistant MCF7-ARO cells. Cell potency of compounds was determined in a 96-hour viability assay.

C.

Supplementary Table 1: Secreted Factor Screen Results. Percent changes in viability of drug treated samples compared to drug treated samples in the presence of a

secreted factor. Each row is for a single secreted factor.

	GDC-0032	(1GDC-0032 (1 μM)	Letrozole (1 µM)	Letrozole (1 µM)
4-1BB Ligand	7%	-3%	-4%	-8%
4-1BB Receptor	7%	2%	14%	19%
Activin-A (Insect cell derived)	4%	-10%	-54%	-50%
Activin-B (Insect cell derived)	2%	-9%	-29%	-29%
AITRL	8%	0%	-6%	-24%
Amphiregulin (98 a.a.)	-3%	4%	16%	5%
ANG-1 (HeLa cell derived)	5%	0%	-5%	-16%
ANG-2 (CHO cell derived)	6%	-2%	-14%	-2%
APRIL (insect cell derived)	10%	1%	-16%	-24%
Artemin	5%	-4%	-12%	-11%
BAFF	7%	-3%	-12%	-3%
BAFF Receptor	-3%	0%	1%	-6%
BCA-1/BLC (CXCL13)	5%	-2%	-25%	-21%
ВСМА	5%	-4%	-10%	-19%
BDNF	7%	-3%	-24%	-15%
beta-NGF	5%	-1%	17%	20%
Betacellulin	19%	13%	81%	86%
BMP-1/PCP	-18%	-18%	-28%	-15%
BMP-13/CDMP-2	5%	12%	56%	65%
BMP-2	6%	-4%	-32%	-36%
BMP-3	-4%	0%	2%	5%
BMP-4 (HeLa cell derived)	1%	-15%	-46%	-38%
MP-4 (truncated; E.coli derive	1%	-7%	-37%	-30%
BMP-6 (HEK 293 cell derived)	3%	-7%	-51%	-40%
BMP-7 (CHO cell derived)	8%	-3%	-14%	-9%
BMP-8a	-13%	0%	12%	-7%
BMP-9	-16%	-12%	-38%	-40%
BRAK (CXCL14)	4%	0%	6%	-11%
Cardiotrophin-1	15%	5%	8%	17%
CCL1/I-309/TCA-3	-18%	-17%	5%	6%
CCL14a/HCC-1	-9%	-3%	13%	-5%
CCL18/PARC	-8%	2%	28%	17%
CCL2/JE/MCP-1	-3%	4%	8%	15%
CCL3/MIP-1 alpha	-4%	-1%	-5%	5%
CCL4/MIP-1 beta	-3%	1%	9%	9%
CCL5/RANTES	-5%	3%	12%	5%
CCL7/MCP-3/MARC	-9%	-1%	4%	-5%

CCL8/MCP-2	-7%	2%	-6%	13%
CD22 (CHO cell derived)	7%	2%	-5%	-4%
CDNF	-4%	-5%	-11%	-18%
Chemerin	1%	-3%	-3%	-14%
CNTF	4%	-5%	-15%	-11%
CTACK (CXL27)	5%	-2%	-7%	-10%
CTGF	5%	-2%	-14%	-7%
CTGFL/WISP-2	3%	-2%	12%	-4%
CXCL1/GRO alpha/KC/CINC-1	-6%	1%	23%	20%
CXCL10/IP-10/CRG-2	-4%	5%	51%	26%
CXCL12/SDF-1 alpha	-6%	4%	30%	-3%
CXCL12/SDF-1 beta	-3%	6%	7%	3%
CXCL16	0%	-5%	-5%	-8%
XCL2/GRO beta/MIP-2/CINC-	-5%	-2%	3%	1%
CL3/GRO gamma/CINC-2/DCI	-4%	1%	-6%	1%
CXCL7/NAP-2	-7%	5%	0%	-2%
CXCL8/IL-8	-3%	1%	6%	11%
CXCL8/IL-8	-11%	-3%	16%	6%
CYR61	10%	4%	30%	26%
DKK-1 (HEK293 cells)	8%	0%	-16%	-35%
E-Selectin (CHO cell derived)	0%	-1%	12%	29%
EG-VEGF	6%	1%	-4%	-9%
EGF (CON)	23%	8%	106%	102%
EGF (CON)	13%	13%	111%	109%
EGF (CON)	23%	11%	100%	114%
EGF (CON)	10%	8%	128%	121%
GF Receptor (CHO cell derived	11%	1%	-12%	-23%
ENA-78/CXCL5 (5-78 a.a.)	6%	-2%	-22%	2%
ENA-78/CXCL5 (8-78 a.a.)	3%	-5%	-10%	-18%
Endostatin	-4%	2%	-5%	-6%
Eotaxin (CCL11)	7%	-2%	-15%	-10%
Eotaxin-2 (CCL24)	7%	-3%	-10%	0%
Eotaxin-3 (CCL26)	4%	-3%	-20%	-5%
Epigen	0%	-4%	-8%	-10%
Epiregulin	0%	1%	50%	46%
Exodus-2 (CCL21)	7%	-5%	4%	3%
Jin A/AHSG (HEK293 cell deriv	-1%	1%	19%	41%
FGF-10	11%	21%	133%	136%
FGF-16	-3%	6%	2%	-2%
FGF-17	-3%	0%	10%	6%
FGF-18	-2%	-1%	8%	38%

FGF-19	-6%	-2%	-10%	-3%
FGF-19 FGF-20	-0% 8%	-2%	-10%	-3%
FGF-20 FGF-21	-6%	-2%	-4%	-10%
FGF-21 FGF-23	-0% 6%	-2%	-3%	-10%
FGF-4	0% 9%	5 <i>%</i> 6%	50%	74%
FGF-5	-4%	-3%	1%	1%
FGF-6	-4% -3%	-3%	42%	33%
FGF-8	-3 <i>%</i> 5%	12%	65%	86%
FGF-8 FGF-9	15%	7%	83%	68%
FGF-acidic	9%	23%	116%	124%
FGF-basic	19%	27%	124%	124%
FGF-basic (CON)	36%	21%	93%	118%
FGF-basic (CON)	22%	23%	112%	132%
FGF-basic (CON)	34%	20%	118%	132%
FGF-basic (CON)	26%	26%	142%	141%
Flt-3 Ligand	-7%	-7%	-18%	7%
Flt3-Ligand	9%	3%	-24%	-22%
Follistatin	5%	-1%	10%	9%
Fractalkine (CX3CL1)	2%	-8%	-20%	-9%
G-CSF	5%	-4%	-30%	-33%
gAcrp30/Adipolean	-5%	8%	6%	2%
gAcrp30/Adipolean Variant	-6%	1%	4%	7%
Galectin-1	-9%	-3%	-12%	4%
Galectin-3	4%	7%	18%	51%
GCP-2 (CXCL6)	2%	-5%	-16%	-18%
GDF-11	0%	-9%	-12%	-15%
F-15/MIC-1 (cell culture deriv	7%	-6%	-16%	-1%
GDF-2 (CHO cell derived)	-3%	-18%	-60%	-57%
GDF-3	5%	-7%	4%	-3%
GDF-5 (BMP-14/CDMP-1)	-6%	-6%	0%	-6%
GDF-7	6%	-2%	-37%	-38%
GDNF	12%	1%	14%	15%
GM-CSF	6%	3%	24%	22%
GMF-beta	11%	3%	7%	11%
GRO-beta (CXCL2)	11%	8%	6%	1%
GRO-gamma (CXCL3)	7%	-7%	-8%	4%
GRO/MGSA (CXCL1)	-6%	-3%	-13%	-12%
HB-EGF	12%	14%	125%	145%
HCC-1/CCL14 (66 a.a.)	10%	-2%	-14%	-17%
HCC-1/CCL14 (72 a.a.)	4%	-4%	-24%	-28%
Heregulin-beta1	31%	37%	165%	192%

HGF (CON)	18%	0%	11%	2%
HGF (CON)	7%	2%	23%	10%
HGF (CON)	16%	1%	27%	8%
HGF (CON)	2%	3%	19%	11%
HGF (Insect cell derived)	9%	-6%	-9%	-22%
HVEM-Fc (Insect cell derived)	-17%	-16%	-23%	-28%
I-309 (CCL1)	10%	0%	-36%	-30%
I-TAC (CXCL11)	5%	3%	17%	3%
ICAM-1 (CHO cell derived)	2%	7%	39%	38%
IFN-beta (CHO cell derived)	-18%	-27%	-48%	-53%
IFN-gamma	-28%	-27%	-65%	-46%
IFN-lambda 1	0%	0%	-3%	-6%
IFN-lambda 2	2%	-2%	0%	-9%
IFN-omega	-16%	-12%	-35%	-26%
IGF-BP1	-4%	-1%	-11%	-1%
IGF-BP2 (insect cell derived)	5%	-1%	-1%	-11%
IGF-BP3	-3%	0%	-8%	-7%
IGF-BP4 (insect cell derived)	3%	-4%	-5%	-6%
IGF-BP5	-5%	-7%	-11%	-3%
IGF-BP6 (insect cell derived)	4%	-3%	-3%	-13%
IGF-BP7	-1%	1%	12%	19%
IGF-I	-7%	-6%	6%	5%
IGF-II	-3%	3%	55%	76%
IL-1 beta/IL-1F2	-21%	-21%	-10%	16%
IL-10	7%	-4%	-13%	-5%
IL-11	11%	6%	-2%	9%
IL-12	0%	6%	78%	51%
IL-12p70 (CHO cell derived)	7%	-2%	-24%	-31%
IL-12p80 (insect cell derived)	9%	0%	-18%	-13%
IL-13	4%	-6%	-31%	-40%
IL-13 Variant	6%	-3%	-30%	-25%
IL-15	9%	-1%	-29%	-12%
IL-16 (121 a.a.)	5%	-5%	-36%	-32%
IL-16 (130 a.a.)	7%	-4%	-10%	-8%
IL-17A	-1%	6%	58%	46%
IL-17B	-1%	1%	11%	-1%
IL-17D	-1%	0%	8%	-8%
IL-17E	-3%	-2%	6%	-12%
IL-17F	-9%	-3%	2%	17%
IL-19	12%	9%	8%	10%
IL-1alpha	-16%	-17%	16%	-4%

IL-1beta	-15%	-20%	4%	-1%
IL-1RA	-8%	-1%	-14%	0%
IL-2	-5%	3%	4%	-6%
IL-20	3%	-4%	-18%	-5%
IL-21	5%	-1%	-10%	2%
IL-22	4%	-5%	-21%	-14%
IL-23 (insect cell derived)	4%	0%	-31%	-17%
IL-3	8%	-7%	-6%	1%
IL-31	7%	4%	10%	-2%
IL-33	-13%	-16%	7%	18%
IL-34 (HEK293 cells)	-7%	-11%	5%	-11%
IL-4	1%	1%	12%	-6%
IL-5	6%	-2%	-14%	-17%
IL-6	-14%	-15%	-15%	-44%
IL-7	-3%	4%	-5%	-29%
IL-8 (72 a.a.) (CXCL8)	-4%	3%	7%	4%
IL-8 (77 a.a.) (CXCL8)	-2%	-2%	1%	8%
IL-9	6%	-3%	-6%	-27%
IP-10 (CXCL10)	-3%	0%	16%	18%
KGF (FGF-7)	33%	26%	116%	133%
KLOTHO (CHO cell derived)	1%	1%	-4%	4%
LAG-1 (CCL4L1)	5%	0%	9%	17%
LD78-beta (CCL3L1)	1%	2%	13%	20%
LEC/NCC-4 (CCL-16)	3%	-2%	-4%	5%
Leptin	-10%	10%	3%	-10%
LIGHT (Insect cell derived)	5%	-2%	10%	11%
Lymphotactin (XCL1)	4%	-2%	4%	6%
M-CSF	9%	-4%	-21%	-22%
MANF	-3%	1%	19%	15%
Maspin	-1%	-4%	6%	3%
MCP-1/MCAF (CCL2)	0%	2%	18%	10%
MCP-2 (CCL8)	7%	1%	20%	9%
MCP-3 (CCL7)	4%	2%	26%	-1%
MCP-4 (CCL13)	6%	0%	3%	9%
MDC (67 a.a.) (CCL22)	2%	0%	-3%	14%
MDC (69 a.a.) (CCL22)	7%	-5%	9%	6%
MEC (CCL28)	4%	1%	13%	2%
Media (+ DRUG)	11%	6%	8%	0%
Media (+ DRUG)	4%	2%	10%	26%
Media (+ DRUG)	13%	4%	16%	23%
Media (+ DRUG)	-2%	3%	9%	7%

Media (+ DRUG)	6%	8%	5%	1%
Media (+ DRUG)	-10%	-15%	-2%	6%
Media (+ DRUG)	6%	0%	-3%	-11%
Media (+ DRUG)	8%	0%	-25%	-8%
Media (+ DRUG)	7%	-2%	-42%	-55%
Media (+ DRUG)	7%	-3%	-15%	-16%
Media (+ DRUG)	6%	-1%	-32%	-11%
Media (+ DRUG)	3%	-3%	-19%	-20%
Media (+ DRUG)	7%	5%	17%	26%
Media (+ DRUG)	1%	4%	19%	-11%
Media (+ DRUG)	1%	0%	-5%	-10%
Media (+ DRUG)	1%	-4%	-4%	-2%
Media (+ DRUG)	-2%	-3%	-11%	7%
Media (+ DRUG)	3%	-4%	-7%	-7%
Media (+ DRUG)	2%	-3%	-12%	-1%
Media (+ DRUG)	1%	-5%	-8%	12%
Media (+ DRUG)	-1%	-1%	23%	15%
Media (+ DRUG)	-1%	5%	7%	-8%
Media (+ DRUG)	-3%	-1%	4%	-5%
Media (+ DRUG)	-7%	0%	-14%	-10%
Media (+ DRUG)	-6%	2%	1%	0%
Media (+ DRUG)	-2%	-1%	-5%	0%
Media (+ DRUG)	-2%	-4%	-12%	-3%
Media (+ DRUG)	-2%	0%	0%	-15%
Media (+ DRUG)	-7%	4%	20%	16%
Media (+ DRUG)	-4%	5%	25%	-2%
Media (+ DRUG)	-8%	6%	3%	10%
Media (+ DRUG)	-7%	2%	7%	2%
Media (+ DRUG)	-3%	-6%	4%	17%
Media (+ DRUG)	-5%	0%	20%	2%
Media (+ DRUG)	-7%	-2%	-3%	7%
Media (+ DRUG)	-10%	3%	22%	17%
Media (NO DRUG)	109%	105%	93%	104%
Media (NO DRUG)	88%	117%	110%	111%
Media (NO DRUG)	111%	103%	100%	106%
Media (NO DRUG)	77%	104%	111%	112%
Media (NO DRUG)	115%	77%	110%	106%
Media (NO DRUG)	92%	100%	97%	102%
Media (NO DRUG)	112%	101%	103%	104%
Media (NO DRUG)	96%	103%	98%	103%
Media (NO DRUG)	107%	103%	107%	86%

Media (NO DRUG)	98%	106%	99%	86%
Media (NO DRUG)	114%	95%	87%	107%
Media (NO DRUG)	98%	100%	99%	92%
Media (NO DRUG)	111%	98%	106%	102%
Media (NO DRUG)	93%	100%	94%	93%
Media (NO DRUG)	109%	99%	107%	97%
Media (NO DRUG)	97%	93%	92%	97%
Media (NO DRUG)	114%	102%	98%	102%
Media (NO DRUG)	85%	103%	102%	111%
Media (NO DRUG)	106%	100%	85%	99%
Media (NO DRUG)	79%	96%	101%	92%
Media (NO DRUG)	107%	103%	95%	95%
Media (NO DRUG)	89%	98%	75%	99%
Media (NO DRUG)	106%	95%	94%	89%
Media (NO DRUG)	147%	158%	219%	223%
Media (NO DRUG)	100%	97%	94%	80%
Media (NO DRUG)	81%	87%	97%	90%
Media (NO DRUG)	102%	88%	93%	90%
Media (NO DRUG)	81%	95%	87%	85%
Media (NO DRUG)	104%	92%	76%	79%
Media (NO DRUG)	81%	99%	90%	85%
Media (NO DRUG)	107%	86%	87%	79%
Media (NO DRUG)	82%	95%	96%	93%
ΜΙΑ	3%	-2%	11%	6%
MIA-2	6%	-6%	8%	2%
Midkine	3%	-4%	6%	11%
MIG (CXCL9)	1%	-1%	29%	8%
MIP-1alpha (CCL3)	6%	1%	26%	-9%
MIP-1beta (CCL4)	4%	1%	-15%	-7%
MIP-3 (CCL23)	4%	-2%	14%	-12%
MIP-3alpha (CCL20)	2%	0%	-2%	3%
MIP-3beta (CCL19)	5%	-3%	16%	0%
MIP-4 (CCL18)	7%	1%	42%	30%
MIP-5 (CCL15)	-4%	5%	0%	-1%
Myostatin	-1%	-2%	-2%	-10%
Myostatin Propeptide	-1%	2%	-12%	15%
NAP-2 (CXCL7)	8%	0%	-12%	-19%
Neuritin	7%	-4%	-2%	6%
Neurturin	13%	1%	18%	46%
NNT-1/BCSF-3	10%	-5%	-16%	-10%
NOGGIN (293 cell derived)	5%	1%	29%	3%

NOV	-1%	-3%	-3%	-2%
NRG1 beta 1 (CON)	34%	20%	131%	164%
NRG1 beta 1 (CON)	24%	19%	151%	194%
NRG1 beta 1 (CON)	33%	24%	147%	174%
NRG1 beta 1 (CON)	23%	22%	150%	158%
NT-3	5%	-2%	-9%	7%
NT-4	5%	7%	23%	6%
Oncostatin-M (209 a.a.)	15%	7%	150%	155%
Oncostatin-M (227 a.a.)	13%	10%	74%	105%
Osteoprotegerin	-7%	1%	-2%	-3%
OTOR	-2%	-4%	-5%	-3%
X40 Ligand (Insect cell derived	4%	1%	1%	-10%
PDGF	-26%	-26%	-43%	-48%
PDGF-AA	3%	1%	-7%	-12%
PDGF-AB	2%	0%	-2%	-5%
PDGF-BB	5%	2%	-10%	-5%
PDGF-CC	1%	2%	12%	-1%
'ECAM-1 (HEK293 cell derived	-5%	-3%	5%	3%
PEDF	4%	4%	16%	12%
Persephin	0%	5%	30%	8%
PF-4 (CXCL4)	2%	5%	-8%	-1%
Pleiotrophin	2%	-3%	-5%	-12%
PIGF-1	-3%	-2%	0%	6%
PIGF-2	-1%	-2%	18%	1%
PIGF-3	-4%	0%	8%	11%
Prokineticin-2	2%	-3%	-7%	-5%
Prolactin	-9%	0%	-4%	-7%
PTHrP	-4%	-3%	-9%	-19%
RANTES (CCL5)	0%	-4%	-8%	-2%
Relaxin-2	-6%	0%	-8%	8%
Relaxin-3	-4%	-3%	19%	19%
RELM-beta	3%	6%	37%	9%
Resistin	-2%	4%	15%	-9%
sCD100 (CHO cell derived)	-1%	-4%	-3%	0%
sCD14 (293 cell derived)	-3%	-3%	-8%	-3%
sCD23	-2%	-1%	1%	4%
CD27 Ligand (CHO cell derivec	-34%	-38%	-82%	-94%
CD30 Ligand (CHO cell derivec	0%	4%	21%	17%
sCD34 (CHO cell derived)	0%	4%	12%	-1%
sCD40 Ligand	-6%	3%	0%	-9%
SCF	2%	1%	-12%	-11%

SCGF-alpha	9%	6%	21%	-6%
SCGF-beta	9% 7%	3%	18%	-8%
SDF-1alpha (CXCL12)	3%	5%		-19%
SDF-1beta (CXCL12)	5% 2%	-2%	-13% -6%	-19%
		-2%		
sDLL-1 (HEK293 cell derived)	-2%		3%	-15%
sDLL-4 (HEK293 cell derived)	-3%	-1%	-4%	1%
sFas Ligand (CHO cell derived)	4%	-3%	4%	-20%
sFas Receptor	-2%	-1%	-4%	-17%
sFRP-1 (HeLa cell derived)	-2%	-1%	1%	-14%
IL-2Ralpha (Insect cell derived	-1%	-4%	11%	-1%
L-4Ralpha (HEK293 cell derive	2%	-4%	-21%	-8%
L-6Ralpha (HEK293 cell derive	0%	-5%	-25%	-13%
Slit2-N (HEK293 cell derived)	2%	2%	3%	7%
Sonic Hedgehog	-2%	-3%	-4%	15%
RC/Osteonectin (CHO cell deri	-26%	-27%	-28%	-33%
sRANK Ligand	10%	-3%	-7%	-13%
sRANK Receptor	-8%	-3%	6%	-9%
sTNF-receptor Type I	-3%	0%	-8%	3%
sTNF-receptor Type II	-1%	-3%	-15%	-2%
sTRAIL receptor-1	-7%	-3%	-9%	-10%
sTRAIL receptor-2	-7%	-5%	-9%	3%
sTRAIL/Apo2L	-16%	-15%	-40%	-30%
TACI	4%	0%	-2%	-6%
TAFA-2	-1%	-5%	-2%	-4%
TARC (CCL17)	0%	6%	1%	10%
TECK (CCL25)	2%	2%	-10%	-11%
TFF-1	-1%	-1%	-4%	-5%
TFF-2	-4%	-5%	-13%	-9%
TFF-3	-4%	-2%	-8%	-13%
TGF-alpha	10%	17%	153%	163%
TGF-beta 1	-31%	-33%	-58%	-65%
TGF-beta 2	-21%	-19%	-37%	-34%
TGF-beta 3	-18%	-20%	-41%	-39%
GF-beta1 (HEK293 cell derived	-7%	-16%	21%	11%
GF-beta2 (HEK293 cell derived	-5%	-12%	-22%	-38%
TGF-beta3	-14%	-15%	-37%	-38%
Thrombopoietin/Tpo	-4%	1%	15%	3%
TL-1A	-2%	0%	2%	-19%
TLR-3 (HEK293 cell derived)	-4%	1%	12%	7%
TNF-alpha	-34%	-40%	-110%	-102%
TNF-beta	-28%	-32%	-54%	-50%

ТРО	8%	1%	-34%	-27%
TSG	-8%	-2%	4%	0%
TSLP	10%	-3%	-16%	-1%
TWEAK	-8%	-4%	12%	27%
TWEAK Receptor	-3%	0%	-4%	-7%
VAP-1 (CHO cell derived)	6%	-3%	-7%	-11%
Vaspin	-2%	1%	6%	2%
VCAM-1 (HEK293 cell derived)	-3%	5%	29%	26%
VEGF-A (121 a.a.)	8%	-1%	-1%	-2%
VEGF-A (165 a.a.)	11%	5%	17%	20%
VEGF-B	-3%	-2%	19%	1%
VEGF-C (HEK293 cell derived)	-4%	-1%	25%	20%
VEGF-D (HEK293 cell derived)	8%	-1%	15%	-4%
Visfatin	7%	23%	115%	116%
WISP-1	0%	0%	-11%	-10%
WISP-3	1%	-3%	14%	3%
WNT-1	9%	-2%	-12%	-12%
Wnt-4	-24%	-24%	-36%	-43%
NNT-7A (HEK 293 cell derived	2%	-9%	-15%	1%
WISP-3	7%	1%	4%	17%
Angiogenin	-4%	-3%	-12%	-10%
AREG / GAS6	-6%	-5%	0%	-2%
BMP-10	-10%	-3%	-18%	-37%
BMP-5	6%	0%	1%	-10%
BOC	2%	-3%	-4%	-17%
Cathepsin S	12%	6%	15%	-5%
CCL11/Eotaxin	14%	11%	21%	16%
CCL13/MCP-4	2%	1%	22%	-4%
CCL14 (two aa forms) / CCL15	-11%	-6%	-21%	-5%
CCL15/MIP-1 delta	3%	2%	28%	-1%
CCL15/MIP-1 delta	4%	3%	6%	-11%
CCL16/HCC-4	-6%	2%	15%	-5%
CCL17/TARC	-4%	2%	7%	-8%
CCL19/MIP-3 beta	8%	0%	5%	-6%
CCL20/MIP-3 alpha	16%	14%	31%	6%
CCL21/6Ckine	1%	14%	21%	-10%
CCL22/MDC	5%	3%	24%	-7%
CCL23/Ck beta 8-1	3%	3%	27%	1%
CCL23/MPIF-1	6%	4%	14%	-2%
CCL24/Eotaxin-2/MPIF-2	0%	-1%	9%	-10%
CCL25/TECK	0%	1%	10%	-11%

CCL26/Eotaxin-3	8%	4%	-20%	-15%
CCL27/CTACK	18%	13%	24%	22%
CCL28	7%	9%	27%	-6%
L1/MIP-1 alpha Isoform LD78	6%	4%	17%	-8%
CCL4L1/LAG-1	1%	6%	24%	1%
CD30 Ligand/TNFSF8	13%	2%	30%	9%
CD40 Ligand/TNFSF5	3%	4%	8%	-5%
CTGF	-6%	-5%	-24%	0%
CX3CL1/Fractalkine	5%	3%	21%	-8%
CXCL11/I-TAC	0%	2%	26%	-1%
CXCL12/SDF-1	3%	5%	13%	-12%
CXCL13/BLC/BCA-1	10%	18%	50%	6%
CXCL14/BRAK	13%	15%	21%	-4%
CXCL17/VCC-1	1%	6%	17%	-6%
CXCL4/PF4	7%	8%	16%	-9%
CXCL5/ENA-70	5%	2%	10%	-14%
CXCL5/ENA-74	3%	10%	13%	7%
CXCL5/ENA-78	4%	4%	23%	1%
CXCL6/GCP-2	6%	4%	11%	-16%
CXCL9/MIG	0%	0%	11%	0%
Decorin	-9%	-5%	-17%	-2%
Desert Hedgehog/Dhh	-2%	6%	21%	-1%
Dkk-2	7%	3%	24%	-1%
Dkk-3	2%	1%	19%	4%
Dkk-4	4%	2%	17%	-1%
DPPIV	7%	5%	18%	4%
Draxin	19%	18%	6%	-8%
EGF	19%	15%	172%	114%
EGF (CON)	18%	26%	173%	124%
EGF (CON)	11%	6%	144%	121%
EGF (CON)	22%	19%	167%	101%
EGF / IL7 / NT3 / Eotaxin	7%	11%	130%	109%
EGF / NRG / FGFb / HGF	32%	30%	228%	167%
Endocan/ESM-1	-1%	3%	21%	1%
Ephrin-A1	1%	-1%	10%	-23%
Ephrin-A3	-2%	3%	-6%	-2%
Ephrin-A3	5% 2%	5%	7%	-15%
Ephrin-A4	3%	-1%	0%	-13%
Ephrin-A4	15%	8%	8%	-6%
Ephrin-A5	-1%	8%	12%	-14%
Ephrin-A5	11%	11%	21%	4%

Enhrin B2	6%	5%	10%	-3%
Ephrin-B3 Ephrin-B3	8%	10%	10%	-3%
•	-13%	0%	-3%	-8%
ephrinB2 EPO	-13%	1%	-20%	-8%
	-9%	-1%	-20%	-9%
Fas Ligand/TNFSF6 FGF-12	-8%	-1%	-1%	
FGF-12 FGF-22	30%	24%	-4%	-5% 81%
FGF-3			97%	
FGF-acidic	21% 41%	26% 37%	97% 198%	71% 148%
FGF-basic		31%		
	30%		177% 204%	120%
FGF-basic (CON)	29%	35%		136%
FGF-basic (CON)	12%	23%	154%	115%
FGF-basic (CON) FGF-BP	31%	33%	187%	135%
-	9%	9%	9%	7%
FGF1 / IL6	27%	27%	174%	137%
FGF2 / CCL3	16%	22%	155%	129%
FGF2 / CCL3 / CCL20	24%	23%	157%	134%
Fibulin 5/DANCE	7%	10%	3%	7%
FLRG	-4%	-6%	1%	-6%
Frizzled-1	2%	3%	9%	-12%
Frizzled-10	-5%	2%	7%	-17%
Frizzled-4	2%	1%	18%	-15%
Frizzled-5	15%	10%	39%	13%
Frizzled-5	2%	9%	29%	-11%
Frizzled-7	3%	3%	23%	2%
Frizzled-8	-3%	6%	-4%	-8%
Gas-6	-6%	0%	20%	22%
GDF-1	22%	21%	100%	72%
GDF-15	-6% 4%	-5%	-11%	-3% 1%
GDF-8/Myostatin GFR alpha-3/GDNF R alpha-3		5%	10%	
	3% 9%	0%	19% 4%	-3%
GITR Ligand/TNFSF18 Gremlin	9% 2%	6% 6%		-8%
			14%	-13%
HGF (CON)	18%	19%	137%	69%
HGF (CON)	-2%	-2%	3%	2%
HGF (CON)	8% 5%	10%	21%	4%
HGF / AREG	-5%	-6% 1.0%	2%	14%
HGF / CCL28	-4%	-10%	-9%	7% 129
HGF / GAS6	-7% วว%	-10%	-8%	-12%
IFN IFN alaba	-22%	-16%	-27%	-48%
IFN-alpha	-12%	-15%	-54%	-44%

IFN-alpha 1	-8%	-4%	-1%	-17%
IFN-alpha 2	-10%	-13%	-33%	-43%
IFN-alpha 4	-1%	-5%	-12%	-20%
IFN-alpha 4	4%	-5%	-25%	-21%
IFN-alpha A	-18%	-21%	-57%	-47%
IFN-alpha B2	-14%	-13%	-58%	-50%
IFN-alpha C	-11%	-15%	-33%	-33%
IFN-alpha D	-5%	-5%	-6%	-11%
IFN-alpha F	-7%	-9%	-15%	-30%
IFN-alpha G	-9%	-9%	-15%	-29%
IFN-alpha H2	-20%	-18%	-59%	-49%
IFN-alpha I	-15%	-16%	-35%	-44%
IFN-alpha J1	5%	0%	0%	-21%
IFN-alpha K	-10%	-1%	-17%	-25%
IFN-alpha WA	-12%	-9%	-21%	-31%
IL-1 alpha/IL-1F1	-13%	-14%	21%	17%
IL-17/IL-17A	3%	1%	17%	2%
IL-17C	9%	5%	26%	-16%
IL-18 / FGFBP1	-5%	-4%	-11%	-11%
IL-18/IL-1F4	0%	-2%	8%	-2%
IL-1F7/FIL1 zeta	10%	5%	22%	4%
IL-24	17%	12%	41%	16%
IL-26/AK155	2%	4%	29%	-30%
IL-26/AK155	18%	13%	22%	-4%
IL-27	0%	2%	20%	-2%
IL-28A/IFN-lambda 2	7%	8%	20%	10%
IL-28B/IFN-lambda 3	7%	5%	16%	5%
IL-29/IFN-lambda 1	10%	7%	5%	0%
IL-32 alpha	-6%	4%	2%	-3%
IL-36 alpha/IL-1F6	8%	6%	23%	13%
IL-36 beta/IL-1F8	5%	5%	35%	3%
IL-36 gamma/IL-1F9	2%	8%	35%	4%
6 / IL8 / GMCSF / CXCL1 / MCI		1%	17%	9%
IL8 / CXCL1 / CXCL2 / CXCL3	-2%	3%	36%	25%
Indian Hedgehog/Ihh	0%	5%	19%	-14%
Insulin	-4%	-6%	24%	15%
Klotho beta	3%	0%	6%	-18%
LEDGF	13%	13%	32%	15%
Lefty-A	2%	2%	8%	-10%
LIF	0%	0%	15%	23%
Media (+ DRUG)	12%	11%	42%	16%

	20/	20/	00/	40/
Media (+ DRUG)	-2%	-3%	-9%	4%
Media (+ DRUG)	7%	10%	40%	4%
Media (+ DRUG)	-9%	-7%	-16%	-8%
Media (+ DRUG)	-6%	-1%	-7%	-5%
Media (+ DRUG)	-7%	-7%	-9%	6%
Media (+ DRUG)	-6%	-5%	-16%	-8%
Media (+ DRUG)	-6%	-9%	-18%	-1%
Media (+ DRUG)	1%	5%	1%	2%
Media (+ DRUG)	0%	0%	-8%	3%
Media (+ DRUG)	-6%	-7%	-8%	7%
Media (+ DRUG)	-6%	-8%	-13%	-3%
Media (+ DRUG)	-9%	-5%	-9%	-6%
Media (+ DRUG)	-4%	-5%	-21%	-7%
Media (+ DRUG)	-7%	-9%	-13%	-11%
Media (+ DRUG)	-3%	-3%	4%	-2%
Media (+ DRUG)	1%	-1%	-12%	0%
Media (+ DRUG)	-4%	-1%	-18%	12%
Media (+ DRUG)	-1%	-3%	-6%	-7%
Media (+ DRUG)	-10%	-6%	-16%	1%
Media (+ DRUG)	-5%	-2%	-11%	-9%
Media (+ DRUG)	-6%	-10%	-5%	1%
Media (+ DRUG)	-5%	-9%	-7%	-7%
Media (+ DRUG)	-5%	-10%	-18%	-12%
Media (+ DRUG)	5%	-3%	-5%	1%
Media (+ DRUG)	4%	4%	-7%	-4%
Media (+ DRUG)	-1%	-3%	-5%	-3%
Media (+ DRUG)	-2%	-5%	-12%	1%
Media (+ DRUG)	-3%	-2%	-20%	-2%
Media (+ DRUG)	-3%	0%	-11%	5%
Media (+ DRUG)	-5%	-3%	-15%	1%
Media (+ DRUG)	1%	-5%	-15%	-1%
Media (+ DRUG)	17%	14%	17%	5%
Media (+ DRUG)	6%	6%	0%	-5%
Media (+ DRUG)	0%	14%	16%	-2%
Media (+ DRUG)	0%	5%	4%	-1%
Media (+ DRUG)	2%	6%	15%	-8%
Media (+ DRUG)	-6%	-2%	-15%	5%
Media (+ DRUG)	5%	2%	23%	0%
Media (+ DRUG)	-1%	-4%	-18%	5%
Media (+ DRUG)	10%	7%	9%	1%
Media (+ DRUG)	1%	-4%	-5%	-2%

Media (+ DRUG)	6%	10%	10%	-7%
Media (+ DRUG) Media (+ DRUG)	-2%	-4%	3%	0%
Media (+ DRUG) Media (+ DRUG)	3%	4%	17%	4%
Media (+ DRUG) Media (+ DRUG)	3% 1%	-7%	-6%	3%
Media (+ DRUG) Media (+ DRUG)	11%	1%	32%	1%
Media (+ DRUG) Media (+ DRUG)	2%	1%	4%	7%
Media (+ DRUG) Media (+ DRUG)	2 <i>%</i> 7%	2%	4% 9%	5%
Media (+ DRUG) Media (+ DRUG)	9%	7%	16%	-5%
Media (+ DRUG) Media (+ DRUG)	5%	0%	-2%	11%
Media (+ DRUG)	5%	5%	-15%	-14%
Media (+ DRUG)	-4%	1%	-11%	-6%
Media (+ DRUG)	-9%	-5%	-15%	-2%
Media (+ DRUG)	3%	-4%	-5%	5%
Media (+ DRUG)	-4%	-1%	-4%	-4%
Media (+ DRUG)	-7%	-5%	-5%	4%
Media (+ DRUG)	-11%	-1%	10%	13%
Media (+ DRUG)	9%	5%	29%	19%
Media (+ DRUG)	7%	12%	19%	-7%
Media (+ DRUG)	11%	8%	13%	-5%
Media (+ DRUG)	5%	6%	23%	-2%
Media (+ DRUG)	5%	5%	16%	8%
Media (+ DRUG)	-1%	5%	11%	-9%
Media (+ DRUG)	4%	4%	16%	2%
Media (+ DRUG)	0%	6%	28%	15%
Media (NO DRUG)	108%	130%	165%	86%
Media (NO DRUG)	92%	103%	86%	90%
Media (NO DRUG)	127%	136%	168%	91%
Media (NO DRUG)	111%	104%	128%	103%
Media (NO DRUG)	123%	132%	158%	103%
Media (NO DRUG)	104%	105%	125%	95%
Media (NO DRUG)	127%	125%	168%	90%
Media (NO DRUG)	109%	105%	128%	110%
Media (NO DRUG)	123%	123%	146%	88%
Media (NO DRUG)	100%	116%	122%	94%
Media (NO DRUG)	120%	121%	164%	104%
Media (NO DRUG)	95%	101%	109%	103%
Media (NO DRUG)	124%	125%	164%	102%
Media (NO DRUG)	103%	105%	114%	99%
Media (NO DRUG)	130%	124%	179%	100%
Media (NO DRUG)	111%	106%	89%	94%
Media (NO DRUG)	114%	128%	145%	95%

	4020/	4040/	0.00/	0.00/
Media (NO DRUG)	103%	101%	90%	96%
Media (NO DRUG)	117%	125%	146%	89%
Media (NO DRUG)	106%	97%	86%	80%
Media (NO DRUG)	132%	124%	134%	95%
Media (NO DRUG)	107%	97%	76%	86%
Media (NO DRUG)	168%	161%	242%	164%
Media (NO DRUG)	95%	89%	89%	97%
Media (NO DRUG)	122%	120%	170%	92%
Media (NO DRUG)	85%	104%	80%	113%
Media (NO DRUG)	109%	128%	137%	84%
Media (NO DRUG)	97%	92%	82%	103%
Media (NO DRUG)	124%	112%	136%	102%
Media (NO DRUG)	90%	92%	76%	104%
Media (NO DRUG)	118%	111%	138%	85%
Media (NO DRUG)	102%	87%	96%	102%
Media (NO DRUG)	108%	105%	95%	102%
Media (NO DRUG)	104%	99%	82%	90%
Media (NO DRUG)	88%	90%	84%	93%
Media (NO DRUG)	95%	86%	79%	101%
Media (NO DRUG)	82%	97%	72%	94%
Media (NO DRUG)	90%	89%	85%	90%
Media (NO DRUG)	86%	96%	91%	82%
Media (NO DRUG)	89%	85%	91%	104%
Media (NO DRUG)	103%	108%	104%	116%
Media (NO DRUG)	97%	94%	80%	87%
Media (NO DRUG)	91%	93%	85%	83%
Media (NO DRUG)	91%	98%	84%	78%
Media (NO DRUG)	96%	89%	83%	87%
Media (NO DRUG)	83%	84%	89%	96%
Media (NO DRUG)	85%	90%	81%	93%
Media (NO DRUG)	77%	93%	96%	110%
Media (NO DRUG)	92%	94%	91%	109%
Media (NO DRUG)	101%	99%	84%	96%
Media (NO DRUG)	91%	102%	70%	101%
Media (NO DRUG)	86%	92%	93%	96%
Media (NO DRUG)	82%	87%	91%	90%
Media (NO DRUG)	84%	91%	84%	105%
Media (NO DRUG)	75%	87%	77%	81%
Media (NO DRUG)	90%	91%	86%	101%
Media (NO DRUG)	117%	98%	97%	123%
Media (NO DRUG)	98%	93%	100%	107%

Media (NO DRUG) 88% 90% 87% 92% Media (NO DRUG) 88% 77% 76% 89% Media (NO DRUG) 91% 95% 62% 104% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 100% 116% 113% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 94% 80% 77% 92%		0.001			
Media (NO DRUG) 88% 77% 76% 89% Media (NO DRUG) 91% 95% 62% 104% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 100% 116% 113% Media (NO DRUG) 100% 108% 112% 99% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 22% 80% 88% Media (NO DRUG) 82% 83% 81% 79% Media (NO DRUG) 82% 83% 81% 89% Media (NO DRUG) 120% 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 90% 87% 96% Media (NO DRUG) 90% 87% 96% Media (NO DRUG) <t< th=""><th>Media (NO DRUG)</th><th>92%</th><th>93%</th><th>102%</th><th>79%</th></t<>	Media (NO DRUG)	92%	93%	102%	79%
Media (NO DRUG) 91% 95% 62% 104% Media (NO DRUG) 85% 88% 85% 93% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 107% 100% 116% 113% Media (NO DRUG) 107% 100% 116% 113% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 83% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 92% 93% 101% Media (NO DRUG) 105%					
Media (NO DRUG) 85% 88% 85% 93% Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 100% 116% 113% Media (NO DRUG) 100% 116% 113% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 83% 81% 79% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 100% 111% 106% 119% Media (NO DRUG)	· · ·				
Media (NO DRUG) 104% 89% 101% 95% Media (NO DRUG) 107% 100% 116% 113% Media (NO DRUG) 100% 108% 112% 99% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 94% 86% 84% 101% Media (NO DRUG) 100% 87% 89% 100% Media (NO DRUG) 100% 109% 95% <td< th=""><th>• •</th><th></th><th></th><th></th><th></th></td<>	• •				
Media (NO DRUG) 107% 100% 116% 113% Media (NO DRUG) 100% 108% 112% 99% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG)	• •				
Media (NO DRUG) 100% 108% 112% 99% Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 91% 80% 77% 92% Media (NO DRUG) 92% 91% 100% 10% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 102% 77% 98%	· · ·				
Media (NO DRUG) 91% 94% 89% 95% Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 100% 10% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 100% 10% 84% 108% Media (NO DRUG) 102% 87% 98% 105%	• •				
Media (NO DRUG) 93% 92% 80% 88% Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 91% 80% 77% 92% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 92% 91% 100% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 100% 111% 106% 119% Media (NO DRUG) 100% 103% 95% 105% Media (NO DRUG) 102% 100% 84% 108% Media	• •				
Media (NO DRUG) 82% 88% 81% 79% Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 91% 80% 77% 92% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 100% 10% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 100% 103% 75% 98% Media (NO DRUG) 102% 100% 84% 108% Media (NO DRUG) 92% 92% 77% 105%<	• •				
Media (NO DRUG) 78% 87% 62% 100% Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 102% 100% 84% 103% Media (NO DRUG) 92% 92% 77% 105% Media (NO DRUG) 93% 93% 102%	• •				
Media (NO DRUG) 86% 89% 81% 89% Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 100% 100% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 100% 84% 108% Media (NO DRUG) 102% 100% 84% 108% Media (NO DRUG) 102% 92% 77% 105% Media (NO DRUG) 93% 93% 92% 92% <					
Media (NO DRUG) 93% 92% 94% 111% Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 100% 12% 100% 108% Media (NO DRUG) 102% 100% 84% 108% Media (NO DRUG) 102% 93% 93% 102% Media (NO DRUG) 93% 93% 89% 102% Media (NO DRUG) 102% 89% 97% 104	• •				
Media (NO DRUG) 120% 109% 90% 125% Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 81% 89% 91% 100% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 102% 100% 84% 108% Media (NO DRUG) 102% 92% 77% 105% Media (NO DRUG) 92% 92% 77% 105% Media (NO DRUG) 93% 93% 89% 102% Media (NO DRUG) 102% 89% 97% 104%					
Media (NO DRUG) 100% 103% 75% 96% Media (NO DRUG) 99% 88% 94% 93% Media (NO DRUG) 81% 89% 91% 100% Media (NO DRUG) 94% 80% 77% 92% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 92% 91% 97% 96% Media (NO DRUG) 90% 87% 89% 100% Media (NO DRUG) 105% 111% 106% 119% Media (NO DRUG) 100% 109% 95% 105% Media (NO DRUG) 102% 100% 84% 108% Media (NO DRUG) 92% 92% 77% 105% Media (NO DRUG) 93% 93% 89% 102% Media (NO DRUG) 102% 89% 97% 104% Media (NO DRUG) 106% 105% 83% 91%	· · ·				
Media (NO DRUG)99%88%94%93%Media (NO DRUG)81%89%91%100%Media (NO DRUG)94%80%77%92%Media (NO DRUG)92%91%97%96%Media (NO DRUG)92%91%97%96%Media (NO DRUG)90%87%89%100%Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)93%93%89%102%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%93%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94% </th <th></th> <th></th> <th></th> <th></th> <th></th>					
Media (NO DRUG)81%89%91%100%Media (NO DRUG)94%80%77%92%Media (NO DRUG)92%91%97%96%Media (NO DRUG)84%86%84%101%Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)100%100%84%108%Media (NO DRUG)102%100%84%108%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)93%93%89%102%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%91%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91% <t< th=""><th>· · ·</th><th></th><th></th><th></th><th></th></t<>	· · ·				
Media (NO DRUG)94%80%77%92%Media (NO DRUG)92%91%97%96%Media (NO DRUG)84%86%84%101%Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)102%100%84%108%Media (NO DRUG)92%92%77%105%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%94%Media (NO DRUG)106%105%87%84%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91% <td< th=""><th>• •</th><th></th><th></th><th></th><th></th></td<>	• •				
Media (NO DRUG)92%91%97%96%Media (NO DRUG)84%86%84%101%Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)102%100%84%108%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%94%Media (NO DRUG)106%97%85%104%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%98%89%108%Media (NO DRUG)106%91% <th>• •</th> <th></th> <th></th> <th></th> <th></th>	• •				
Media (NO DRUG)84%86%84%101%Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)102%100%84%108%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%93%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	· · ·				
Media (NO DRUG)90%87%89%100%Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)104%84%72%98%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)101%105%83%91%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	• •				
Media (NO DRUG)105%111%106%119%Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)104%84%72%98%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)94%89%97%104%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%91%Media (NO DRUG)90%102%87%103%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%92%85%104%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%95%97%Media (NO DRUG)106%98%89%108%Media (NO DRUG)106%91%95%97%	• •				
Media (NO DRUG)100%109%95%105%Media (NO DRUG)102%100%84%108%Media (NO DRUG)104%84%72%98%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)106%105%83%91%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	• •	90%		89%	100%
Media (NO DRUG)102%100%84%108%Media (NO DRUG)104%84%72%98%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)102%89%97%104%Media (NO DRUG)101%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	• •	105%	111%	106%	119%
Media (NO DRUG)104%84%72%98%Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)102%89%97%104%Media (NO DRUG)101%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)90%102%87%94%Media (NO DRUG)90%102%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%108%Media (NO DRUG)106%91%94%108%Media (NO DRUG)106%91%95%97%	· · ·	100%		95%	
Media (NO DRUG)92%92%77%105%Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)101%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%108%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%95%97%	• •	102%	100%	84%	108%
Media (NO DRUG)93%93%89%102%Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)111%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%95%97%					
Media (NO DRUG)94%84%84%103%Media (NO DRUG)102%89%97%104%Media (NO DRUG)111%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	· · ·	92%	92%	77%	105%
Media (NO DRUG)102%89%97%104%Media (NO DRUG)111%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	Media (NO DRUG)	93%	93%	89%	102%
Media (NO DRUG)111%110%97%108%Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	• •	94%	84%	84%	103%
Media (NO DRUG)106%105%83%91%Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)106%91%94%108%Media (NO DRUG)106%115%95%97%	• •	102%	89%	97%	104%
Media (NO DRUG)103%93%75%94%Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%		111%	110%	97%	108%
Media (NO DRUG)90%102%87%103%Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	· · ·	106%	105%	83%	91%
Media (NO DRUG)95%87%88%93%Media (NO DRUG)95%92%85%104%Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%	• •	103%	93%	75%	94%
Media (NO DRUG) 95% 92% 85% 104% Media (NO DRUG) 106% 89% 90% 84% Media (NO DRUG) 106% 91% 94% 106% Media (NO DRUG) 125% 98% 89% 108% Media (NO DRUG) 106% 115% 95% 97%	· · ·	90%	102%	87%	103%
Media (NO DRUG)106%89%90%84%Media (NO DRUG)106%91%94%106%Media (NO DRUG)125%98%89%108%Media (NO DRUG)106%115%95%97%		95%	87%	88%	93%
Media (NO DRUG) 106% 91% 94% 106% Media (NO DRUG) 125% 98% 89% 108% Media (NO DRUG) 106% 115% 95% 97%		95%	92%	85%	104%
Media (NO DRUG) 125% 98% 89% 108% Media (NO DRUG) 106% 115% 95% 97%	· · ·			90%	
Media (NO DRUG) 106% 115% 95% 97%	• •	106%	91%	94%	106%
	· · ·	125%	98%	89%	108%
	• •	106%	115%	95%	97%
Media (NO DRUG) 108% 104% 89% 93%	Media (NO DRUG)	108%	104%	89%	93%

Media (NO DRUG)	100%	95%	78%	96%
Media (NO DRUG)	82%	93%	89%	97%
Media (NO DRUG)	104%	93%	97%	95%
Media (NO DRUG)	83%	93%	76%	107%
Media (NO DRUG)	101%	88%	83%	105%
Media (NO DRUG)	117%	109%	113%	104%
Media (NO DRUG)	97%	101%	108%	112%
Media (NO DRUG)	92%	104%	94%	105%
Media (NO DRUG)	89%	97%	98%	98%
Media (NO DRUG)	100%	92%	112%	102%
Media (NO DRUG)	107%	97%	94%	91%
Media (NO DRUG)	99%	93%	109%	98%
Media (NO DRUG)	89%	96%	99%	114%
Media (NO DRUG)	117%	106%	105%	117%
Media (NO DRUG)	119%	121%	104%	124%
Media (NO DRUG)	95%	102%	115%	123%
Media (NO DRUG)	84%	94%	110%	126%
Media (NO DRUG)	105%	94%	100%	118%
Media (NO DRUG)	86%	107%	103%	117%
Media (NO DRUG)	89%	107%	85%	125%
Media (NO DRUG)	85%	95%	97%	118%
MIS/AMH	2%	0%	25%	-7%
MMP-1	-1%	-1%	8%	1%
MMP-10	-4%	-5%	-17%	2%
MMP10 / ANG1	14%	12%	73%	59%
leuregulin-1 alpha/NRG1 alph	28%	32%	230%	152%
euregulin-1 beta 1/NRG1 beta	33%	26%	255%	168%
Neuregulin-1 Isoform SMDF	28%	30%	272%	186%
Neuregulin-1/NRG1	12%	17%	237%	151%
Neuropilin-1	10%	11%	31%	0%
Neuropilin-2	8%	4%	24%	1%
Nidogen-1	-9%	-5%	3%	-11%
Nodal	1%	2%	13%	-9%
NRG1 beta 1 (CON)	45%	46%	282%	193%
NRG1 beta 1 (CON)	15%	13%	222%	171%
NRG1 beta 1 (CON)	27%	26%	233%	152%
Oncostatin M/OSM	6%	8%	164%	101%
Osteoprotegerin/TNFRSF11B	8%	5%	10%	-5%
PAI-I	-6%	0%	-9%	3%
PDGF-DD	5%	2%	15%	-5%
Pentraxin 3/TSG-14	-6%	2%	10%	-6%

PIGF	-8%	-12%	-9%	15%
Progranulin/PGRN	-1%	2%	4%	-13%
R-Spondin 1	2%	2%	6%	-10%
R-Spondin 2	6%	2%	-21%	-16%
R-Spondin 3	7%	8%	24%	-3%
R-Spondin 4	3%	7%	29%	-6%
RANK/TNFRSF11A	-1%	3%	21%	-6%
sFRP-3	8%	14%	31%	2%
sFRP-4	3%	-1%	14%	-12%
sFRP-5	1%	-2%	11%	-1%
Soggy-1/DkkL1	4%	1%	25%	3%
SOST/Sclerostin	1%	3%	8%	-20%
TAFA1/FAM19A1	-3%	2%	-5%	-2%
TAFA2/FAM19A2	1%	4%	-2%	-17%
TAFA4/FAM19A4	9%	16%	13%	-1%
TAFA5/FAM19A5	9%	14%	2%	-6%
Thrombospondin	-7%	-3%	0%	-8%
TIMP1	4%	0%	-7%	9%
TIMP2	-8%	1%	0%	3%
TIMP2 / Osteoprotegerin	-6%	-7%	-9%	-16%
TIMP2 / SPARC	-5%	-8%	-7%	-7%
TL1A/TNFSF15	12%	13%	55%	31%
TRAIL/TNFSF10	-17%	-17%	-69%	-66%
TRANCE/TNFSF11/RANK L	3%	2%	27%	-3%
TROY/TNFRSF19	6%	3%	-1%	2%
uPAR	-8%	-5%	-16%	-7%
VEGF	-1%	3%	5%	-7%
VIP	-4%	-4%	0%	-6%
WIF-1	1%	7%	33%	-11%
WISP1	-3%	1%	-15%	-2%
Wnt-11	-1%	2%	12%	-4%
Wnt-3a	-1%	1%	13%	-11%
Wnt-5a	3%	2%	17%	-10%
XCL1/Lymphotactin	-3%	-1%	-4%	-13%